Know Cancer

or
forgot password

Open, Multicenter Observational Study of Docetaxel Utilized in Mono- or Combination Therapy for the Treatment of Breast Cancer, Non-small Cell Lung Cancer, Prostata-carcinoma, Adenocarcinoma of the Stomach and Advanced Squamous Cell Carcinoma of the Head/Neck Region.


N/A
N/A
N/A
Open (Enrolling)
Both
Carcinoma

Thank you

Trial Information

Open, Multicenter Observational Study of Docetaxel Utilized in Mono- or Combination Therapy for the Treatment of Breast Cancer, Non-small Cell Lung Cancer, Prostata-carcinoma, Adenocarcinoma of the Stomach and Advanced Squamous Cell Carcinoma of the Head/Neck Region.


Inclusion Criteria:



- Indication for Docetaxel according to the SmPC and treating physician

Exclusion Criteria:

- according to the Docetaxel SmPC

Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Outcome Measure:

the quantity of Doce onkovis needed pro treatment cycle

Outcome Description:

Determine the quantity of Doce onkovis needed pro treatment cycle

Outcome Time Frame:

the time the participants will be followed depends on the number of treatment cycles; that means the time frame may extend up to 24 weeks (8 cycles).

Safety Issue:

No

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

ONKODOC 01

NCT ID:

NCT01614002

Start Date:

May 2012

Completion Date:

April 2014

Related Keywords:

  • Carcinoma
  • carcinoma
  • breast cancer
  • non-small cell lung cancer
  • prostata cancer
  • adenocarcinoma of the stomach
  • squamous cell carcinoma of the head and neck region
  • ambulant chemotherapy
  • treatment cycles
  • Docetaxel
  • Doce onkovis
  • Quantity of Docetaxel
  • Packaging Sizes
  • Adenocarcinoma
  • Breast Neoplasms
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Squamous Cell
  • Stomach Neoplasms

Name

Location